Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CPT1A | P50416 | 5/20 | 0.37 |
| ▸ | CPT2 | P23786 | 3/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724804 | 0.80 | PREP (0.42) | GRM5ACE | |
| SCHEMBL5725319 | 0.73 | MEN1 (0.41) | — | |
| SCHEMBL5742919 | 0.72 | ACE (0.61) | GRM5ACEACE2 | |
| SCHEMBL5742925 | 0.72 | ACE (0.61) | GRM5ACEACE2 | |
| SCHEMBL5725406 | 0.68 | OPRM1 (0.38) | FAAHACHE | |
| SCHEMBL31236804 | 0.67 | GAA (0.58) | GAA | |
| SCHEMBL27911893 | 0.64 | GPR35 (0.53) | GAA | |
| SCHEMBL31324114 | 0.64 | SPHK1 (0.57) | CPT1ACPT2ACEACE2 | |
| SCHEMBL21494262 | 0.62 | GFER (0.52) | — | |
| SCHEMBL21494263 | 0.62 | GFER (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246810-B1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | ORTHO MCNEIL PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6518285-B2 | 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1246810-A1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001046164-A1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | OXA1L, RPS27L, RPS27 | GRM5 3846/4885FAAH 4101/4885ACHE 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.